Intravitreal aflibercept 8 mg showed improvements in best corrected visual acuity for patients with diabetic macular edema in a diverse cohort. Data presented at Academy 2024 demonstrated meaningful gains regardless of age, gender, race, ethnicity, acuity, or central retinal thickness. The PHOTON trial compared aflibercept 8 mg and 2 mg in patients with DME, finding similar visual improvements across demographic groups. Patients with worse baseline BCVA showed greater gains compared to those with better baseline BCVA. The study was sponsored by Regeneron Pharmaceuticals and co-funded by Bayer AG, with no relevant financial disclosures from the researchers.
Source link
Aflibercept 8 mg improves vision in DME, with similar outcomes by age, sex, race
